RE: EsoBiotec Accomplishments17 Mar 2025 08:28
CAR-T cell therapy, while effective for some cancers, can cause side effects, including a neurological condition called Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) which can manifest as encephalopathy, and in rare cases, encephalitis.
Here's a more detailed explanation:
1. ICANS and Encephalopathy:
ICANS:
This is a common side effect of CAR-T cell therapy, characterized by a range of neurological symptoms.
Encephalopathy:
ICANS can manifest as encephalopathy, a condition affecting brain function, with symptoms including confusion, agitation, and in some cases, seizures.
ICANS Symptoms:
Other symptoms of ICANS can include tremor, aphasia (difficulty with speech), impaired handwriting, and lethargy.
Timing:
ICANS typically occurs within the first few weeks after CAR-T cell infusion.
Reversibility:
With appropriate supportive care and medications like steroids, ICANS is often reversible.
2. Encephalitis:
HHV-6 Encephalitis:
In some cases, CAR-T cell therapy can be associated with Human Herpesvirus 6 (HHV-6) encephalitis, a serious neurological condition.
Distinguishing from ICANS:
It can be difficult to distinguish HHV-6 encephalitis from ICANS, both can cause neurological symptoms.
Symptoms of HHV-6 Encephalitis:
Symptoms can include headache, confusion, and in some cases, anterograde amnesia (difficulty forming new memories).
Late-Onset Encephalitis:
Rarely, a fatal, late-onset CAR T-cell-mediated encephalitis has been observed, suggesting that the underlying mechanisms of CAR T-cell-induced neurotoxicity may be more complex than initially thought.
Importance of Early Detection:
Early detection and treatment are crucial for managing both ICANS and HHV-6 encephalitis, as they can be life-threatening.
3. Other Neurological Side Effects:
Tremors, Seizures, and Confusion:
Besides encephalopathy, other neurological side effects of CAR-T cell therapy can include tremors, seizures, and confusion.
Cytokine Release Syndrome (CRS):
A common side effect of CAR-T cell therapy is CRS, a systemic inflammatory response that can lead to fever, fatigue, and other symptoms, which can also affect the nervous system.
Management:
ICANS and other neurological side effects are managed with supportive care, medications like steroids, and in some cases, other treatments to address specific symptoms.
4. Key Considerations:
ICANS is a spectrum:
The severity of ICANS can vary, ranging from mild to severe, with some cases being fatal.
Monitoring is crucial:
Patients undergoing CAR-T cell therapy need close monitoring for neurological symptoms, and healthcare professionals should be aware of the possibility of ICANS and other neurological complications.
Research is ongoing:
Researchers are continuing to study the mechanisms of CAR-T cell-induced neurotoxicity and develop strategies to prevent and treat these complica
Sign In
Follow the stocks
